4//SEC Filing
HALKUFF DAWN 4
Accession 0001867096-25-000112
CIK 0001867096other
Filed
Jun 3, 8:00 PM ET
Accepted
Jun 4, 7:03 PM ET
Size
6.0 KB
Accession
0001867096-25-000112
Insider Transaction Report
Form 4
HALKUFF DAWN
Director
Transactions
- Award
Common Stock
2025-06-04+50,000→ 157,500 total
Holdings
- 5,410(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders.
- [F2]The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Documents
Issuer
Xeris Biopharma Holdings, Inc.
CIK 0001867096
Entity typeother
Related Parties
1- filerCIK 0001743658
Filing Metadata
- Form type
- 4
- Filed
- Jun 3, 8:00 PM ET
- Accepted
- Jun 4, 7:03 PM ET
- Size
- 6.0 KB